Unknown

Dataset Information

0

Recent updates on CAR T clinical trials for multiple myeloma.


ABSTRACT: Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autologous stem cell transplantation also showed activity in RRMM. Dual- target CAR T cells are in clinical trials for RRMM. This review summarized the recent updates of ongoing CAR T clinical trials for multiple myeloma.

SUBMITTER: Lin Q 

PROVIDER: S-EPMC6829852 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Recent updates on CAR T clinical trials for multiple myeloma.

Lin Quande Q   Zhao Juanjuan J   Song Yongping Y   Liu Delong D  

Molecular cancer 20191105 1


Proteasome inhibitors, immunomodulatory agents and monoclonal antibodies have dramatically changed the natural history of multiple myeloma (MM). However, most patients eventually suffer a relapse and succumb to the disease. Chimeric antigen receptor (CAR) engineered T cells targeting B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and light chains are in active development for therapy of refractory /relapsed (RR) MM. CD19- targeted CAR T cells in conjunction with autol  ...[more]

Similar Datasets

| S-EPMC10441644 | biostudies-literature
| S-EPMC9746433 | biostudies-literature
| S-EPMC10082521 | biostudies-literature
| S-EPMC10385907 | biostudies-literature
| S-EPMC7713173 | biostudies-literature
| S-EPMC4995679 | biostudies-literature
| S-EPMC8589080 | biostudies-literature
| S-EPMC7727578 | biostudies-literature
| S-EPMC7137578 | biostudies-literature